Batiraxcept, a recombinant fusion protein that inhibits AXL by binding to its activating ligand Growth Arrest-Specific 6, is currently being evaluated in a phase 1/2b study in combination with cabozantinib for patients with advanced ccRCC. Here, AXL is linked to nonpapillary renal cell carcinoma.